Ziopharm Oncology (ZIOP) Reports In-Line Q1 EPS
- Wall Street ekes out gains to close languid week
- 'Faster than Porsche but Safer than Volvo': Tesla (TSLA) Begins Model S Plaid Deliveries, Priced Between $131,100 and $145,600
- Oil hits multi-year highs in third weekly gain on demand recovery
- Snowflake (SNOW) Falls Following Investor Day Despite Strong Guidance, Analysts Bullish But Say Investors May Have Wanted More
- Dollar looks stronger as euro and sterling dip
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Ziopharm Oncology (NASDAQ: ZIOP) reported Q1 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Cash and cash equivalents, as of March 31, 2021 were $100.1 million.
For earnings history and earnings-related data on Ziopharm Oncology (ZIOP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chewy (CHWY) Tops Q1 EPS by 12c, Revs Beat Slightly
- Navigator Holdings Ltd. (NVGS) Reports In-Line Q1 EPS
- Dave & Buster's Entertainment (PLAY) Beat Q1 Revenues, Guides Q2 Revenues Above the Street
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!